IN8bio, Inc. announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer (COO). Dr. Rochlin previously served as Vice President, Operations and Innovation. Dr. Rochlin will be responsible for multiple functional areas, including chemistry, manufacturing and controls (CMC), technical operations, laboratory operations as well as collaborative development of preclinical pipeline and clinical translational programs. Dr. Rochlin will also continue to work with early innovation programs and partners. At IN8bio, Dr. Rochlin has led several areas of operations and corporate development, including key contributions to successful initial public offering (IPO) in August 2021. Dr. Rochlin has also been responsible for the development of analytical, quality and manufacturing teams and spearheading the buildout of the Company’s planned 10,000 sq. ft. research laboratory in Birmingham, AL. Prior to joining IN8bio, Dr. Rochlin gained extensive expertise in company development at Curadigm, where she served as Chief Business Officer, Nanobiotix, Filament Biosolutions and Immunovent, the latter of which she co-founded and served as Chief Scientific Officer. At these companies she conducted scientific research, managed intellectual property strategy, oversaw business development and managed company operations, including corporate strategy, partnering and team development. Dr. Rochlin was recognized in 2019 as one of the top women in tech by Crain’s New York Business. Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College and conducted research at the Memorial Sloan Kettering Cancer Center. She earned a B.A. in Biology from the University of Pennsylvania.